| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Common Stock | Sale | -$351K | -35.3K | -0.87% | $9.93 | 4.03M | Apr 9, 2025 | Direct | F1, F2, F3 |
| transaction | ARWR | Common Stock | Sale | -$36.6K | -3.4K | -0.08% | $10.75 | 4.02M | Apr 9, 2025 | Direct | F1, F3, F4 |
| transaction | ARWR | Common Stock | Sale | -$19K | -1.62K | -0.04% | $11.76 | 4.02M | Apr 9, 2025 | Direct | F1, F3, F5 |
| transaction | ARWR | Common Stock | Sale | -$544K | -50K | -1.24% | $10.87 | 3.97M | Apr 10, 2025 | Direct | F1, F3 |
| transaction | ARWR | Common Stock | Sale | -$584K | -50.8K | -1.28% | $11.49 | 3.92M | Apr 11, 2025 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | Sale of securities to cover taxes associated with the vesting of restricted stock awards |
| F2 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.67 to $ 10.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F3 | Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| F4 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 10.51 to $ 11.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F5 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 11.49 to $ 12.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |